What is NASH?
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD). It is characterized by the accumulation of fat in the liver along with inflammation and liver cell damage. NASH can progress to cirrhosis, liver failure, or even hepatocellular carcinoma.
Histological Features of NASH
In histology, the diagnosis of NASH is based on specific features observed under the microscope. Key features include:-
Steatosis: This refers to the accumulation of fat within liver cells. In NASH, the steatosis is typically macrovesicular, meaning large fat droplets displace the nucleus to the cell periphery.
-
Lobular Inflammation: This involves the presence of inflammatory cells, such as lymphocytes and neutrophils, within the hepatic lobules.
-
Hepatocyte Ballooning: A hallmark of NASH, ballooning degeneration refers to the swelling of hepatocytes due to cellular damage.
-
Fibrosis: Over time, repeated liver damage can result in the formation of scar tissue. Fibrosis in NASH often starts in zone 3 (centrilobular) and can progress to bridging fibrosis and cirrhosis.
Pathogenesis of NASH
The exact causes of NASH are complex and multifactorial. Important mechanisms include:-
Insulin Resistance: This is a key driver of NAFLD and NASH. It leads to increased lipolysis and free fatty acid delivery to the liver, promoting steatosis.
-
Oxidative Stress: Excessive fat in the liver undergoes oxidation, generating reactive oxygen species (ROS) that damage hepatocytes.
-
Inflammation: Chronic low-grade inflammation, often due to adipokines and cytokines from adipose tissue, exacerbates liver injury.
-
Genetic Factors: Certain genetic polymorphisms, such as those in the PNPLA3 and TM6SF2 genes, can predispose individuals to NASH.
Histological Staging and Grading
The severity of NASH is often assessed using the
NAFLD Activity Score (NAS) and fibrosis staging. The NAS includes components such as steatosis, lobular inflammation, and hepatocyte ballooning. Fibrosis staging ranges from F0 (no fibrosis) to F4 (cirrhosis).
Clinical Implications of Histological Findings
Histological assessment is crucial for:-
Diagnosis: Distinguishing NASH from simple steatosis and other liver conditions.
-
Prognosis: The extent of fibrosis is a strong predictor of clinical outcomes in NASH patients.
-
Treatment: Guiding therapeutic decisions and monitoring response to interventions.
Therapeutic Approaches
Currently, there are no FDA-approved medications specifically for NASH. However, lifestyle modifications such as diet and exercise are recommended. Experimental treatments targeting various pathways involved in NASH pathogenesis are under investigation.
